GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

I also offer Esketamine ( Spravato) for clients suffer from Treatment ... working with adults 18 years and older struggling with anxiety, depression, bipolar, schizophrenia, trauma, and stressor ...

For those with major depression, there is a new treatment option - one that offers hope when patients are not responding to existing treatment. The ...

Moreover, on January 21, 2025, the FDA approved Spravato for the treatment of MDD ... and potential in Alzheimer's psychosis, general anxiety disorder and others. So we see Intra-Cellular as ...

Greenbrook treatment centers also offer SPRAVATO ® (esketamine ... as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the immediate impact Spravato has had on patients with treatment-resistant ...

It can be challenging to know what to do if you have a partner with anxiety. Understanding how anxiety can manipulate your loved one's thoughts, feelings, and behaviors can help you defuse tense ...

(MENAFN- EIN Presswire) Spravato® (esketamine) has been approved for use as a standalone treatment for depression, without the requirement of an accompanying antidepressant. Spravato, previously ...

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

"Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et ...